Wire · regulatory
Oculis Receives FDA Pre-IND Feedback Supporting Privosegtor Development in Acute MS Relapses
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 August 2026 · Fusion42 review
Oculis received supportive FDA pre-IND feedback for Privosegtor's clinical development targeting acute multiple sclerosis relapses, with IND submission planned for Q4 2026. The FDA endorsed the proposed trial design, including patient enrollment criteria and dosing consistent with ongoing studies.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your MS drug development path just cleared a major FDA procedural hurdle that lets you reuse existing data and skip extra preclinical studies. This opens the door to a faster IND submission and trial start, so prioritise patient recruitment and endpoint validation now.
◆ Coverage
1 source · 3 Aug 2026
◆ Related on Wire
◆ Topics